| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Courses and Workshops |
|
|
| |
| |
| |
September 24, 2004 |
|
|
| |
|
|
| |
|
|
|
Srategic Research Institute, Hyatt Regency Cambridge - Cambridge, MA
November 8-9, 2004
Strategic Research Institute’s inaugural International Conference on Vascular Targeting Agents is aimed at understanding the difference between agents that are anti-angiogenic and anti-vascular in nature, the latter not merely inhibiting the formation of vessels but able to damage existing aberrant vessels.Work will be presented from all of the major players in the industry along with academic veterans in the field. Focus will further demarcate the difference between normal and tumor vessels, methodologies to identify therapeutic agents which specifically target such aberrant vessels and case studies of therapeutic agents that are both in the clinic along with novel entities in preclinical development.
|
|
|
|
|
|
|
|
Organized by:
|
|
Strategic Research Institute |
|
|
Invited Speakers:
|
|
Agents that effect neovasculature have now become mainstream with the approval of Avastin, Genentech’s neutralizing monoclonal antibody against vascular endothelial growth factor (VEGF).To date, there are over 60 agents that have entered the clinic designed to inhibit neovascularization, and well over 100 agents in preclinical development. Although many of these agents do indeed inhibit the formation of tumor vessels (“anti-angiogenic”), not all fit into this designation.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
$1395.00 Discounts available for university, hospital and government employees.
|
|
|
E-mail:
|
|
info@srinstitute.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|